103 related articles for article (PubMed ID: 22335020)
1. Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.
Komiyama S; Aoki D; Saitoh E; Komiyama M; Udagawa Y
Eur J Gynaecol Oncol; 2011; 32(6):611-4. PubMed ID: 22335020
[TBL] [Abstract][Full Text] [Related]
2. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study.
Okuda T; Saito H; Sekizawa A; Shimizu Y; Akamatsu T; Kushima M; Yanaihara T; Okai T; Farina A
Gynecol Oncol; 2001 Sep; 82(3):427-34. PubMed ID: 11520136
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors].
Zhang CY; Guo HY; Li H; Wen HW; Liang XD; Qiao J
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):688-91. PubMed ID: 23159083
[TBL] [Abstract][Full Text] [Related]
5. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
8. Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer.
Akahane T; Sekizawa A; Okuda T; Kushima M; Saito H; Okai T
Int J Gynecol Pathol; 2005 Oct; 24(4):369-76. PubMed ID: 16175084
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
10. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival.
Li B; Jin H; Yu Y; Gu C; Zhou X; Zhao N; Feng Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1347-52. PubMed ID: 20009888
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
12. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.
Yamamoto S; Tsuda H; Yoshikawa T; Kudoh K; Kita T; Furuya K; Tamai S; Matsubara O
Am J Surg Pathol; 2007 Jul; 31(7):999-1006. PubMed ID: 17592265
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
[TBL] [Abstract][Full Text] [Related]
14. Survival probability in ovarian clear cell adenocarcinoma.
Kennedy AW; Markman M; Biscotti CV; Emery JD; Rybicki LA
Gynecol Oncol; 1999 Jul; 74(1):108-14. PubMed ID: 10385560
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
16. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
Ho CM; Lin MC; Huang SH; Huang CJ; Lai HC; Chien TY; Chang SF
Gynecol Oncol; 2009 Feb; 112(2):307-13. PubMed ID: 19007975
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
[TBL] [Abstract][Full Text] [Related]
18. Proliferative activity of early ovarian clear cell adenocarcinoma depends on association with endometriosis.
Komiyama S; Aoki D; Katsuki Y; Nozawa S
Eur J Obstet Gynecol Reprod Biol; 2006 Jul; 127(1):130-6. PubMed ID: 16442693
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
van der Burg ME; Henzen-Logmans SC; Berns EM; van Putten WL; Klijn JG; Foekens JA
Int J Cancer; 1996 Dec; 69(6):475-9. PubMed ID: 8980250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
